Press Release: European Medicines Agency recommends restricting use of Pandemrix

Author (Corporate)
Series Title
Series Details EMA/CHMP/568830/2011 (21.7.11)
Publication Date 21/07/2011
Content Type

The review of Pandemrix, an (H1N1) influenza vaccine, was initiated to investigate a possible link between Pandemrix vaccination and narcolepsy, following an increased number of reported cases of narcolepsy among children and adolescents in Finland and Sweden. The reported cases of narcolepsy occurred following the H1N1 pandemic vaccination campaign in late 2009 and early 2010.

Narcolepsy is a rare sleep disorder that causes a person to fall asleep suddenly and unexpectedly.
Source Link http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/07/news_detail_001312.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp
Related Links
EurActiv, 27.7.11: Member states halt 'narcoleptic' flu jabs http://www.euractiv.com/en/health/member-states-halt-narcoleptic-flu-jabs-news-506776
EMA: Press Release: EMA/CHMP/568830/2011 (21.7.11) http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/07/WC500109182.pdf
ECDC: News, 21.7.11: EMA's Committee for Medicinal Products for Human Use (CHMP) issues opinion on narcolepsy and vaccination with Pandemrix® http://www.ecdc.europa.eu/en/press/news/Lists/News/ECDC_DispForm.aspx?List=32e43ee8%2De230%2D4424%2Da783%2D85742124029a&ID=465&RootFolder=%2Fen%2Fpress%2Fnews%2FLists%2FNews
Subject Categories
Countries / Regions